



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	10/712,795-Conf. #6394
Filing Date	November 13, 2003
First Named Inventor	Rosanne M. Crooke
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	30566/39634

### U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	5,220,006-B1	06-15-1993	Ross et al.	
	A2	5,656,612-B1	08-12-1997	Monia	
	A3	5,786,206-B1	07-28-1998	Smith et al.	
	A4	6,096,516-B1	08-01-2000	Kwak et al.	
	A5	6,156,315-B1	12-05-2000	Goldberg et al.	

### FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO 99/18986-A1	04-23-1999			
	B2	EPO-0 944 344	04-28-1999			
	B3	WO 01/12789	02-22-2001			
	B4	WO 01/30354	05-03-2001			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Boren et al., "A Simple and Efficient Method for Making Site-directed Mutants, Deletions, and Fusions of large DNA Such as P1 and BAC Clones," <i>Genome Research</i> , 1123-1130 (1996).	
	C2	Branch, "A Good Antisense Molecule is Hard to Find," <i>TBS</i> 23:45-50 (1998).	
	C3	Davidson et al., "Apolipoprotein B:mRNA Editing, Lipoprotein Assembly, and Presecretory Degradation," <i>Annu. Rev. Nutr.</i> 20: 169-193 (2000).	
	C4	Deeb et al., "Chromosomal localization of the human apolipoprotein B gene and detection of homologous RNA in monkey intestine," <i>Proc. Natl. Acad. Sci USA</i> 83:419-422 (1986).	
	C5	Farese et al., "Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes," <i>Proc. Natl. Acad. Sci USA</i> 92:1774-1778 (1995).	
	C6	Hajjar et al., "The Role of Lipoprotein(a) In Atherogenesis and Thrombosis," <i>Annu. Rev. Med.</i> 47:423-442 (1996).	
	C7	Innerarity et al., "Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding," <i>Proc. Natl. Acad. Sci USA</i> 84:6919-6923 (1987).	
	C8	Katan et al., "Characteristics of Human Hypo- and Hyper- responders to Dietary Cholesterol," <i>American Journal of Epidemiology</i> 125(3):387-399 (1987).	
	C9	Kim et al., "Genetically modified mice for the study of apolipoprotein B," <i>Journal of Lipid Research</i> 39: 703-723 (1998).	
	C10	Law et al., "Human apolipoprotein B-100: Cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2," <i>Proc. Natl. Acad. Sci. USA</i> 82:8340-8344 (1985).	

Examiner Signature	<i>[Signature]</i>	Date Considered	4-11-06
-----------------------	--------------------	--------------------	---------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/712,795-Conf. #6394		
		Filing Date	November 13, 2003		
		First Named Inventor	Rosanne M. Crooke		
		Art Unit	1636		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	30566/39634

	C11	McCormick et al., "Transgenic Mice Expressing Human ApoB95 and ApoB97," <i>The Journal of Biological Chemistry</i> 272(38):23616-23622 (1997).	
	C12	Nishina et al., "Synthetic low and high fat diets for the study of atherosclerosis in the mouse," <i>Journal of Lipid Research</i> 31:859-869 (1990).	
	C13	Sandkamp et al., "Lipoprotein(a) Is an Independent Risk Factor for Myocardial Infarction at a Young Age," <i>Clin. Chem.</i> 36/1:20-23 (1990).	
	C14	Seed et al., "Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary heart Disease in Patients with Familial Hypercholesterolemia," <i>The New England Journal of Medicine</i> 1494-1498 (1990).	
	15	Tang Quidong et al., "The Inhibition of Antisense Oligodeoxynucleotides on the Expression of Apolipoprotein B in Rat Liver Cells," <i>Chinese Journal of Arteriosclerosis</i> 7(4):315-318 (1999).	
	C16	Veniant et al., "Susceptibility to Atherosclerosis in Mice expressing Exclusively Apolipoprotein B48 or Apolipoprotein B100," <i>J. Clin. Invest</i> 100(1):180-188 (1997).	
	C17	Vessby et al., "Diverging effects of Cholestyramine on Apolipoprotein B and Lipoprotein Lp(a)," <i>Atherosclerosis</i> 44:61-71 (1982).	
	C18	Chin, Andrew "On the Preparation and Utilization of Isolated and Purified Oligonucleotides." Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on March 14, 2002	
	C19	Eggerman et al. "Use of Oligonucleotides to Target Nucleic Acid Sequences Encoding Apolipoprotein B to Decrease Serum Apolipoprotein B and Cholesterol Levels" Federal Register Volume 65, Number 110 (2000)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9-11-06
--------------------	---	-----------------	---------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/712,795-Conf. #6394		
		Filing Date	November 13, 2003		
		First Named Inventor	Rosanne M. Crooke		
		Art Unit	1636		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	30566/39634

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
<i>JE</i>	A6	60/159,462	N/A	Eggerman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Jeffrey Ford</i>	Date Considered	4-11-06
-----------------------	---------------------	--------------------	---------

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/712,795  
 Filing Date November 13, 2003  
 First Named Inventor Rosanne M. Crooke  
 Art Unit 1633  
 Examiner Janet Epps Ford  
 Attorney Docket No. ISIS.003CPI

(Multiple sheets used when necessary)

SHEET 1 OF 1

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
<i>JE</i>	1	60/159,462	N/A	Eggerman et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>


## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>

1961741\_1  
092905

Examiner Signature <i>Janet Epps Ford</i>	Date Considered <i>4-11-06</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.



Duplicate  
see  
Reference  
A6  
of IDS  
filed  
6-13-05



PTO/SB/08 Equivalent

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)  SHEET 1 OF 1	Application No.	10/712,795
	Filing Date	November 13, 2003
	First Named Inventor	Crooke, et al.
	Art Unit	1633
	Examiner	Janet L. Epps-Ford
	Attorney Docket No.	DOC-0216US (ISIS.003CP1)

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
<i>JE</i>	1	5,945,290	08-31-1999	Cowsert, Lex M.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
<i>JE</i>	2	TANG, et al. 1999. The Inhibition of Antisense Oligodeoxynucleotides on the Expression of Apolipoprotein B in Rat Liver Cells. <i>Chinese Journal of Arteriosclerosis</i> , Vol.7, No.4.	

2258064/LRR  
010306

Examiner Signature <i>Janet L. Epps-Ford</i>	Date Considered <i>7-11-06</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

# SUPPLEMENTAL INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/712,795
Filing Date	November 13, 2003
First Named Inventor	Rosanne Crooke
Art Unit	1633
Examiner	Not yet assigned
Attorney Docket No.	DOC-0216US (ISIS.003CP1)

### U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
<i>SR</i>	1.	WO 99/35241	7/15/1999	Rhone-Poulenc Rorer Pharmaceuticals, Inc.		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>

2491206/LRR  
033106

Examiner Signature	<i>John A. Gysler</i>	Date Considered	4-11-06
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.